Mixed results from a study focused on lower back pain left analysts wanting as well as confused about Vertex's plans to forge ...

Oppenheimer downgraded Vertex Pharmaceuticals (VRTX) to Perform from Outperform without a price target after the company announced results from ...

Lack of NaV1.7 activity leads to the inability to sense pain, whereas NaV1.7 gain of function leads to severe pain. Modulation of NaV1.7, therefore, should be an effective mechanism for decreasing ...

Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced results from its Phase 2 study of suzetrigine for painful ...

An archived webcast will be available on the company's website. About the Phase 2 Suzetrigine Lumbosacral Radiculopathy (LSR) Study This phase 2, 12-week, randomized, double-blind, placebo-controlled ...

Vertex Pharmaceuticals (VRTX) announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain ...

Vertex's closely watched drug, suzetrigine, reduced sciatica pain compared to baseline but did not outperform a placebo ...

Vertex said the Phase II trial met its primary endpoint, however there was only a minor difference to placebo.

Vertex Pharmaceuticals announced results of a midstage trial of its non-opioid experimental painkiller in chronic back pain, ...

Barclays lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $418 from $509 and keeps an Equal Weight rating on the shares. The firm says the Phase 2 painful lumbosacral radiculopathy ...